Retour

Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock

Stocks Company Announcement

- Conversions Eliminate All Variable Priced Derivative Securities

GlobeNewswire Inc. • 07/05/2024 à 15:30:00
Allarity Therapeutics, Inc. Common Stock
Address: 24 SCHOOL ST., 2ND FLOOR
Postal Code: 02108
City: BOSTON
State: MA
Phone Number: 401-426-4664
Website: https://www.allarity.com
Status: Active
Company Info

Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.

List Date2021-12-21
MarketStocks
LocalUS
Primary ExchangeXNAS
TypeCS
Currency NameUSD
CIK0001860657
Composite figiBBG012NXCZP8
Share Class figiBBG012NXCZQ7
Market Cap1,648,246 USD
SIC Code2834
SIC DescriptionPHARMACEUTICAL PREPARATIONS
Total Employees6
Share Class Shares Outstanding17610000
Weighted Shares Outstanding2579414
Round Lot100
Updated date2024-05-19
Stats
Last 5 days
18-05
17-05
16-05
15-05
14-05
Last
0.638
0.66
0.683
0.685
0.745
Variance
0%
-3.65%
0.29%
-12.63%
-5.82%
Open
0.638
0.685
0.681
0.784
0.791
Highest
0.638
0.705
0.713
0.784
0.954
Lowest
0.638
0.705
0.713
0.764
0.924
History
PeriodVarhighestlowest
1 week
-20.45%
0.836
0.638
1 month
-54.1%
1.506
0.638
3 month
54.85%
0.433
0.259
6 month
24%
0.534799
0.259
1 year
-95.03%
13
0.259
3 year
-100%
25480
0.259
5 year
-100%
25480
0.259
10 year
-100%
25480
0.259
Stock Financials
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-11 2023-08-14 2023-11-14 UNPUB
Assets 12,702,000 13,426,000 13,875,000 UNPUB
Current Assets 2,966,000 3,686,000 4,387,000 UNPUB
Current Liabilities 11,588,000 12,668,000 15,744,000 UNPUB
Equity -3,102,000 -723,000 -3,379,000 UNPUB
Equity Attributable To Noncontrolling Interest 0 0 0 UNPUB
Equity Attributable To Parent -3,102,000 -723,000 -3,379,000 UNPUB
Liabilities 13,041,000 14,149,000 17,254,000 UNPUB
Liabilities And Equity 12,702,000 13,426,000 13,875,000 UNPUB
Noncurrent Assets 9,736,000 9,740,000 9,488,000 UNPUB
Noncurrent Liabilities 1,453,000 1,481,000 1,510,000 UNPUB
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-11 2023-08-14 2023-11-14 UNPUB
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 0 0 0 UNPUB
Net Cash Flow, Continuing 0 0 0 UNPUB
Net Cash Flow From Financing Activities 1,158,000 2,865,000 6,450,000 UNPUB
Net Cash Flow From Financing Activities, Continuing 1,158,000 2,865,000 6,450,000 UNPUB
Net Cash Flow From Investing Activities 2,043,000 -369,000 -1,074,000 UNPUB
Net Cash Flow From Investing Activities, Continuing 2,043,000 -369,000 -1,074,000 UNPUB
Net Cash Flow From Operating Activities -3,201,000 -2,496,000 -5,376,000 UNPUB
Net Cash Flow From Operating Activities, Continuing -3,201,000 -2,496,000 -5,376,000 UNPUB
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-11 2023-08-14 2023-11-14 UNPUB
Comprehensive Income/Loss -3,389,000 -2,229,000 -4,539,000 UNPUB
Comprehensive Income/Loss Attributable To Noncontrolling Interest -121,000 180,000 0 UNPUB
Comprehensive Income/Loss Attributable To Parent -3,268,000 -2,409,000 -4,539,000 UNPUB
Other Comprehensive Income/Loss -3,389,000 -2,229,000 -4,539,000 UNPUB
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-11 2023-08-14 2023-11-14 UNPUB
Basic Earnings Per Share -4 -26 -2 UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share -4 -26 -2 UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -3,352,000 -2,380,000 -4,447,000 UNPUB
Income/Loss From Continuing Operations Before Tax -3,352,000 -2,380,000 -4,447,000 UNPUB
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating 92,000 142,000 34,000 UNPUB
Net Income/Loss -3,352,000 -2,380,000 -4,447,000 UNPUB
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Net Income/Loss Attributable To Parent -3,352,000 -2,380,000 -4,447,000 UNPUB
Net Income/Loss Available To Common Stockholders, Basic -3,356,000 -9,786,000 -5,552,000 UNPUB
Operating Expenses 3,659,000 4,156,000 4,426,000 UNPUB
Operating Income/Loss -3,659,000 -4,156,000 -4,426,000 UNPUB
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 4,000 7,406,000 1,105,000 UNPUB
Preferred Stock Dividends And Other Adjustments 4,000 7,406,000 1,105,000 UNPUB
Revenues 0 0 0 UNPUB
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-27 2022-10-07 2022-11-14 2023-03-13
Assets 31,290,000 23,231,000 18,134,000 14,544,000
Current Assets 17,211,000 10,119,000 6,061,000 4,968,000
Current Liabilities 12,711,000 11,462,000 12,955,000 11,222,000
Equity 14,732,000 7,966,000 1,447,000 -113,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 14,732,000 7,966,000 1,447,000 -113,000
Liabilities 14,416,000 13,149,000 14,631,000 12,654,000
Liabilities And Equity 31,290,000 23,231,000 18,134,000 14,544,000
Noncurrent Assets 14,079,000 13,112,000 12,073,000 9,576,000
Noncurrent Liabilities 0 0 1,676,000 1,432,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-27 2022-10-07 2022-11-14 2023-03-13
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 0 -11,465,000 -4,408,000 -17,337,000
Net Cash Flow, Continuing 0 -11,465,000 -4,408,000 -17,337,000
Net Cash Flow From Financing Activities 4,946,000 -7,257,000 0 -1,311,000
Net Cash Flow From Financing Activities, Continuing 4,946,000 -7,257,000 0 -1,311,000
Net Cash Flow From Investing Activities 809,000 0 0 791,000
Net Cash Flow From Investing Activities, Continuing 809,000 0 0 791,000
Net Cash Flow From Operating Activities -5,755,000 -4,208,000 -4,408,000 -16,817,000
Net Cash Flow From Operating Activities, Continuing -5,755,000 -4,208,000 -4,408,000 -16,817,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-27 2022-10-07 2022-11-14 2023-03-13
Comprehensive Income/Loss -3,080,000 -5,103,000 -5,274,000 -16,179,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 406,000 0
Comprehensive Income/Loss Attributable To Parent -3,294,000 -5,517,000 -5,680,000 -16,179,000
Other Comprehensive Income/Loss 0 0 -5,274,000 -121,000
Other Comprehensive Income/Loss Attributable To Parent -3,080,000 UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-27 2022-10-07 2022-11-14 2023-03-13
Basic Earnings Per Share -1 -1 -1 -2
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share -1 -1 -1 -2
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -3,080,000 -5,103,000 -5,037,000 -16,058,000
Income/Loss From Continuing Operations Before Tax -3,080,000 -5,103,000 -5,032,000 -17,579,000
Income Tax Expense/Benefit -1,227,000 4,000 5,000 -1,521,000
Interest Expense, Operating UNPUB UNPUB 35,000 12,000
Net Income/Loss -3,080,000 -5,103,000 -5,037,000 -16,058,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -3,080,000 -5,103,000 -5,037,000 -16,058,000
Net Income/Loss Available To Common Stockholders, Basic -3,080,000 -5,103,000 -5,037,000 -16,058,000
Operating Expenses 18,309,000 4,842,000 4,562,000 34,463,000
Operating Income/Loss -18,309,000 -4,842,000 -4,562,000 -34,463,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 1,377,000 0 0
Revenues 0 0 0 0
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB UNPUB 2022-05-17
Assets UNPUB UNPUB UNPUB 49,633,000
Current Assets UNPUB UNPUB UNPUB 21,054,000
Current Liabilities UNPUB UNPUB UNPUB 20,719,000
Equity UNPUB UNPUB UNPUB 18,152,000
Equity Attributable To Noncontrolling Interest UNPUB UNPUB UNPUB 0
Equity Attributable To Parent UNPUB UNPUB UNPUB 18,152,000
Liabilities UNPUB UNPUB UNPUB 30,849,000
Liabilities And Equity UNPUB UNPUB UNPUB 49,633,000
Noncurrent Assets UNPUB UNPUB UNPUB 28,579,000
Noncurrent Liabilities UNPUB UNPUB UNPUB 10,130,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB UNPUB 2022-05-17
Exchange Gains/Losses UNPUB UNPUB UNPUB 116,000
Net Cash Flow UNPUB UNPUB UNPUB 19,885,000
Net Cash Flow, Continuing UNPUB UNPUB UNPUB 19,769,000
Net Cash Flow From Financing Activities UNPUB UNPUB UNPUB 33,819,000
Net Cash Flow From Financing Activities, Continuing UNPUB UNPUB UNPUB 33,819,000
Net Cash Flow From Investing Activities UNPUB UNPUB UNPUB 1,000,000
Net Cash Flow From Investing Activities, Continuing UNPUB UNPUB UNPUB 1,000,000
Net Cash Flow From Operating Activities UNPUB UNPUB UNPUB -15,050,000
Net Cash Flow From Operating Activities, Continuing UNPUB UNPUB UNPUB -15,050,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB UNPUB 2022-05-17
Comprehensive Income/Loss UNPUB UNPUB UNPUB -28,623,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest UNPUB UNPUB UNPUB 0
Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB -28,623,000
Other Comprehensive Income/Loss UNPUB UNPUB UNPUB -1,975,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB UNPUB 2022-05-17
Basic Earnings Per Share UNPUB UNPUB UNPUB -4
Benefits Costs and Expenses UNPUB UNPUB UNPUB 0
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB 25,209,000
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax UNPUB UNPUB UNPUB -26,648,000
Income/Loss From Continuing Operations Before Tax UNPUB UNPUB UNPUB -1,347,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB 133,000
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss UNPUB UNPUB UNPUB -26,648,000
Net Income/Loss Attributable To Noncontrolling Interest UNPUB UNPUB UNPUB 0
Net Income/Loss Attributable To Parent UNPUB UNPUB UNPUB -26,648,000
Net Income/Loss Available To Common Stockholders, Basic UNPUB UNPUB UNPUB -26,648,000
Operating Expenses UNPUB UNPUB UNPUB 26,556,000
Operating Income/Loss UNPUB UNPUB UNPUB -26,556,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic UNPUB UNPUB UNPUB 0
Preferred Stock Dividends And Other Adjustments UNPUB UNPUB UNPUB 0
Revenues UNPUB UNPUB UNPUB -1,347,000
Calendar
19 May 2024 (Time UTC) Actual Previous Consensus
★★★
15:30
United States
17 May 2024 (Time UTC) Actual Previous Consensus
★
15:30
United States
-17800.000
★
15:30
United States
-60000.000
★
15:30
United States
53700.000
★
15:30
United States
-135800.000
★★
15:30
United States
4400.000
★
15:30
United States
215400.000
★
15:30
United States
-31400.000
★
15:30
United States
62600.000
★
15:30
United States
1300.000
★
15:30
United States
-9700.000
★
15:30
United States
199600.000
★★
15:30
United States
★
15:30
United States
★
15:30
United States
News Stream
Stocks Company Announcement
Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances
- Phase 2 Trial of Stenoparib Concluded Early due to Clear Clinical Benefits Achieved
GlobeNewswire Inc. • 4d ago
Stocks Company Announcement
Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock
- Conversions Eliminate All Variable Priced Derivative Securities
GlobeNewswire Inc. • 1w ago
Stocks Company Announcement
Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1
- Stockholders’ equity significantly surpasses the $2.5 million minimum required by Nasdaq
GlobeNewswire Inc. • 1w ago
Stocks Company Announcement
Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer
Boston (May 2, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced the early discontinuation of its Phase 2 clinical trial of stenoparib, a novel PARP inhibitor, for the treatment of advanced recurrent ovarian cancer. The patients enrolled in the trial had been pre-screened by Allarity’s unique Drug Response predictor (DRP®) companion diagnostic (CDx) in order to treat only patients with the highest likelihood of deriving clinical benefit.
GlobeNewswire Inc. • 2w ago
Stocks Company Announcement
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
Boston (April 29, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that on April 27, 2024, it received formal notice from The Nasdaq Stock Market, LLC’s Office of General Counsel (“Nasdaq”). This notice confirmed that the Company has regained compliance with the minimum bid price requirement as set forth in Nasdaq’s Listing Rule 5550(a)(2) (the “Bid Price Rule”). Nasdaq noted that since April 9, 2024, Allarity’s stock has maintained a closing bid price above $1.00 per share for more than ten consecutive trading days, thereby meeting the requirements for regaining compliance.
GlobeNewswire Inc. • 2w ago
Stocks Company Announcement
Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)
Boston (April 17, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that it had been granted an extension until May 14, 2024, to regain compliance with Nasdaq Listing Rule 5550(b)(1).
GlobeNewswire Inc. • 1mo ago
Stocks Company Announcement
Allarity Therapeutics Announces 1-for-20 Reverse Stock Split
Boston (April 4, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced the implementation of a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20 (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 9:30 a.m. Eastern Time on April 9, 2024. The Company’s common stock will begin trading on a split-adjusted basis when the market opens on April 9, 2024. This strategic move aims to regain compliance with the Nasdaq’s minimum bid price requirement, alongside achieving other operational benefits. The CUSIP number for the Company’s common stock following the Reverse Stock Split will be 016744401.
GlobeNewswire Inc. • 1mo ago
Stocks Company Announcement
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
GlobeNewswire Inc. • 1mo ago
stocks Company Announcement
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
GlobeNewswire Inc. • 1mo ago
stocks Company Announcement
Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)
Boston (March 25, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that the Company has been granted a formal extension until April 24, 2024 to regain compliance under Nasdaq Listing Rules 5550(a)(2) (the “Bid Price Rule”) and 5550(b)(1) (the “Equity Rule”) or any of the alternative requirements in Listing Rule 5550(b).
GlobeNewswire Inc. • 1mo ago
See All
Related
Latest

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT